Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Overall Survival in Patients with HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated with a CDK4/6 Inhibitor plus Fulvestrant: An FDA Pooled Analysis

2021 Year in Review - Breast Cancer - Breast Cancer

Cyclin-dependent kinase (CDK)4/6 inhibitors are oral targeted medicines that are licensed for use in combination with endocrine therapy as a first- or second-line treatment for patients with hormone receptor (HR)-positive, HER2-negative, advanced or metastatic breast cancer.1 CDK4/6 inhibitors with endocrine therapy benefited all clinicopathologic subgroups of patients with HR-positive, HER2-negative, advanced or metastatic breast cancer, so CDK4/6 inhibitors with endocrine therapy appear to help patients whose tumors have varying degrees of endocrine sensitivity.2

Randomized studies of CDK4/6 inhibitors or placebo in combination with fulvestrant in patients with breast cancer submitted to the US Food and Drug Administration before August 1, 2020, were studied.1 All patients studied were aged ≥18 years; had an Eastern Cooperative Oncology Group performance status of 0-1; had advanced or metastatic HR-positive, HER2-negative breast cancer; and had received ≥1 doses of a CDK4/6 inhibitor or placebo in combination with fulvestrant. Patients were looked at as a whole, by the number of previous lines of systemic endocrine therapy used in any illness scenario (first-line or endocrine-naïve vs second-line and later), and by clinicopathologic subgroups of interest. Because of potential patient heterogeneity, the estimated median overall survival was not presented by group when the pooled sample included patients treated across lines of therapy.1

Between 2013 and 2016, 1960 participants were randomly allocated to 1 of 3 pooled trials. Patients were randomly assigned to CDK4/6 inhibitors and 652 (33%) to placebo.1 In all treated patients (N = 1948), the estimated hazard ratio for overall survival was 0.77, with a median follow-up of 43.7 months. Among patients who received CDK4/6 inhibitors or placebo in conjunction with fulvestrant as second-line or later systemic endocrine therapy, the difference in predicted median overall survival favoring CDK4/6 inhibitors was 7.1 months.1

In all pooled patients and throughout most clinicopathologic categories of relevance, adding CDK4/6 inhibitors to fulvestrant resulted in a consistent overall survival advantage.

References

  1. Gao JJ, Cheng J, Prowell TM, et al. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2021;22:1573-1581. Erratum in: Lancet Oncol. 2021;22:e472.
  2. Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21:250-260.
Related Items
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
February 2022 Clinical Trials to Clinical Practice published on February 3, 2022 in Clinical Trials, Breast Cancer
2021 Breast Cancer Year in Review Introduction
2021 Year in Review - Breast Cancer published on January 21, 2022 in Breast Cancer
Copyright © The Lynx Group, LLC. All rights reserved.